On-going combination immunotherapy trials in urothelial cancer
| Therapy | Number | Phase | Trial ID | Est. Completion |
|---|---|---|---|---|
| Nivolumab +/− Ipilimumab (CheckMate-032) | 115070 | I/IIII | NCT01928394NCT02553642 | December 2018September 2018 |
| Atezolizumab + MOXR0916 (anti-OX40) +/− Bevacizumab | 762 | I | NCT02410512 | August 2018 |
| CPI-444 + Atezolizumab | 534 | I/Ib | NCT02655822 | June 2018 |
| Pembrolizumab + PLX3397 (CSF1R) | 400 | I/II | NCT02452424 | July 2019 |
| BMS-986106 (anti-LAG3) +/− Nivolumab | 360 | I/II | NCT01968109 | October 2019 |
| MK-7684 +/− Pembrolizumab | 336 | I | NCT02964013 | March 2020 |
| GSK3174998 (anti-OX40) +/− Pembrolizumab | 264 | I | NCT02528357 | January 2020 |
| Pembrolizuamb + Lenvatinib | 250 | Ib/II | NCT02501096 | January 2018 |
| Durvalumab + Epacadostat | 185 | I/II | NCT02318277 | January 2018 |
| Pembrolizumab + Ramucirumab | 155 | I | NCT02443324 | June 2018 |
| Nivolumab + Cabozantinib +/− Ipilimumab | 135 | I | NCT02496208 | December 2017 |
| Atezolizumab + Epacadostat | 118 | I | NCT02298153 | November 2020 |
| Durvalumab + (Olaparib or Vistusertib orAZD1775 or AZD4547) | 110 | I | NCT02546661 | March 2019 |
| Durvalumab + Tremelimumab + polyICLC (TLR3 agonist) | 102 | I/II | NCT02643303 | August 2022 |
| Pembrolizuamb +/− Acalabrutinib | 75 | II | NCT02351739 | Summer 2017 |
| Tremelimumab +/− Durvalumab | 64 | II | NCT02527434 | October 2018 |
| Ipilimumab + Enoblituzumab (anti-B7-H3) | 59 | I | NCT02381314 | March 2018 |
| Atezolizumab + B-701 (FGFR3 inhibitor) | 48 | Ib | NCT03123055 | April 2017 |
| Pembrolizumab + Vorinostat | 42 | I | NCT02619253 | May 2018 |
| Pembrolizumab + Docetaxel or Gemcitabine | 38 | I | NCT02437370 | December 2019 |
| Nivolumab + Enadenotucirev (oncolytic virus) | 30 | I | NCT02636036 | June 2018 |
| Avelumab + NHS-IL-12 | 30 | I | NCT02994953 | April 2018 |
| Pembrolizumab + Paclitaxel | 27 | II | NCT02581982 | March 2019 |
| Nivolumab + IFN-γ | 15 | I | NCT02614456 | December 2017 |